Steven P Balk
Overview
Explore the profile of Steven P Balk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
8659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ummarino S, Poluben L, Ebralidze A, Autiero I, Ebralidze A, Zhang Y, et al.
Res Sq
. 2025 Feb;
PMID: 39975922
Coordinated initiation of DNA replication is essential to ensure efficient and timely DNA synthesis. Yet, molecular mechanism describing how replication initiation is coordinated in eukaryotic cells is not completely understood....
2.
Poluben L, Nouri M, Liang J, Chen S, Varkaris A, Ersoy-Fazlioglu B, et al.
Cell Rep
. 2024 Dec;
44(1):115089.
PMID: 39709604
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in castration-resistant prostate cancer, but the extent to which they drive AR activity is unclear. We...
3.
Rahman R, Rahaman M, Hanson A, Choo N, Xie J, Townley S, et al.
Br J Cancer
. 2024 Oct;
131(10):1719.
PMID: 39448861
No abstract available.
4.
Huang R, Giafaglione J, Hashimoto T, Zhang L, Yu W, Rao J, et al.
J Clin Transl Pathol
. 2024 Oct;
3(2):49-58.
PMID: 39363910
Background And Objectives: Men have higher morbidity and mortality from COVID-19 than women, possibly due to androgen receptor-regulated viral entry protein expression. This led to a clinical trial of androgen...
5.
Westaby D, Jimenez-Vacas J, Figueiredo I, Rekowski J, Pettinger C, Gurel B, et al.
J Clin Invest
. 2024 Sep;
134(18).
PMID: 39286979
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage...
6.
Rahman R, Rahaman M, Hanson A, Choo N, Xie J, Townley S, et al.
Br J Cancer
. 2024 Aug;
131(6):1092-1105.
PMID: 39117800
Background: Cyclin-dependent kinase 9 (CDK9) stimulates oncogenic transcriptional pathways in cancer and CDK9 inhibitors have emerged as promising therapeutic candidates. Methods: The activity of an orally bioavailable CDK9 inhibitor, CDKI-73,...
7.
Gui F, Jiang B, Jiang J, He Z, Tsujino T, Takai T, et al.
bioRxiv
. 2024 Jul;
PMID: 39026842
Current treatments for advanced prostate cancer (PCa) primarily target the androgen receptor (AR) pathway. However, the emergence of castration-resistant prostate cancer (CRPC) and resistance to AR pathway inhibitors (APSIs) remains...
8.
Nouri M, Varkaris A, Ridinger M, Dalrymple S, Dennehy C, Isaacs J, et al.
Mol Cancer Ther
. 2024 Jun;
23(10):1404-1417.
PMID: 38894678
Polo-like kinase 1 (PLK1) inhibitors have had limited antitumor efficacy as single agents, and focus of current efforts is on combination therapies. We initially confirmed that the PLK1-specific inhibitor onvansertib...
9.
Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, et al.
J Clin Invest
. 2024 Apr;
134(11).
PMID: 38687617
One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and constitutively active AR splice variants, particularly AR-V7....
10.
Poluben L, Nouri M, Liang J, Varkaris A, Ersoy-Fazlioglu B, Voznesensky O, et al.
bioRxiv
. 2024 Jan;
PMID: 38260576
Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in prostate cancer (PC) that develops resistance to androgen signaling inhibitor drugs, but the extent to...